Salt Crystal Forms of a Factor B Inhibitor for Drug Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for glomerulonephritis, particularly IgA nephropathy and C3 glomerulopathy, lack effective small-molecule drugs targeting the complement pathways, and the structural form of pharmaceutical active ingredients can affect drug stability, leading to issues like poor crystallinity and stability.
Innovation Solution
Development of pharmaceutically acceptable salts and crystal forms of the nitrogen-containing bridged heterocyclic derivative 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octan-1-yl)benzoic acid, including various acid salts and their specific crystal forms, which are characterized by distinct X-ray powder diffraction patterns.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If pharmaceutical active ingredients are used in their basic structural form, then the drug can be synthesized and produced, but the drug exhibits poor crystallinity and stability
Solution Approach 1:
The patent applies parameter changes by modifying the physical and chemical state of the drug through salt formation. The basic structural form of the nitrogen-containing bridged heterocyclic derivative is converted into pharmaceutically acceptable salts (such as hydrochloride, sulfate, phosphate salts), which fundamentally changes the crystalline properties and stability parameters of the drug substance, thereby resolving the contradiction between poor crystallinity and instability.
Solution Approach 2:
The patent creates composite materials by forming salt compounds between the active pharmaceutical ingredient and pharmaceutically acceptable acids. These composite salt forms combine the therapeutic activity of the original compound with the beneficial crystalline properties and stability of the salt counterions, achieving both good crystallinity and enhanced stability simultaneously.
2Ease of manufacture
If the drug is produced without salt formation, then the synthesis process is simpler, but the drug exhibits poor flowability and agglomeration
Solution Approach 1:
The patent changes the physical parameters of the drug substance through salt formation, which fundamentally alters the surface properties and interparticle interactions. The resulting salt forms exhibit improved flowability and reduced agglomeration, making the drug easier to handle in pharmaceutical manufacturing processes while maintaining synthesis feasibility through established salt formation methodologies.
3Stability of the object's composition
If salt forms of the drug are developed, then the chemical stability and purity are enhanced, but the device complexity increases
Solution Approach 1:
The patent applies universality by selecting pharmaceutically acceptable salts that serve multiple functions simultaneously: they enhance chemical stability, improve crystallinity, ensure good flowability, and maintain biocompatibility. By choosing from established pharmaceutically acceptable acid counterions, the patent achieves multiple benefits without requiring development of entirely new complex structures, thus managing complexity while maximizing stability improvements.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The proposed salts and crystal forms enhance the chemical stability and purity of the drug, addressing issues of agglomeration and poor flowability, and provide a potential therapeutic option for inhibiting Factor B, a key component of the complement alternative pathway.
Implementation Method 1
which are characterized by distinct X-ray powder diffraction patterns
Data Source
AI summary
Provided are a pharmaceutically acceptable salt and a crystal form of a nitrogen-containing bridge heterocyclic derivative, and a method for preparing same. Specifically provided are different salt forms and crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid, and a method for preparing same. The provided crystal forms of salts of 4-((1S,3S,5R)-3-ethoxy-8-((5-methoxy-7-methyl-1H-indol-4-yl)methyl)-8-azabicyclo[3.2.1]octyl-1-yl)benzoic acid have good stability and can be better used for clinical treatment.